4 - LENSAR, Inc. (0001320350) (Issuer)

4 - LENSAR, Inc. (0001320350) (Issuer)

4 - LENSAR, Inc. (0001320350) (Issuer)

4 - LENSAR, Inc. (0001320350) (Issuer)

4 - LENSAR, Inc. (0001320350) (Issuer)

4 - LENSAR, Inc. (0001320350) (Issuer)

4 - LENSAR, Inc. (0001320350) (Issuer)

4 - LENSAR, Inc. (0001320350) (Issuer)

4 - LENSAR, Inc. (0001320350) (Issuer)

4 - LENSAR, Inc. (0001320350) (Issuer)

         24 ALLY Robotic Laser Cataract Systems™ placed in 3Q 2024 including 11 sales in EU and Southeast Asia; Robust backlog with 24 systems pending installation as of September 30, 2024 38% Revenue growth over third quarter 2023 and 22% Recurring revenue growth in twelve-month trailing average Worldwide procedure volumes increased 29% over third quarter of 2023 Installed system base grew 20% over third quarter of 2023 ORLANDO, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- LENSAR®, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter

ORLANDO, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's third quarter 2024 financial results will be released before market open on Thursday, November 7, 2024. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, November 7, 2024 to discuss the financial results and recent corporate highlights. To participate by telephone, please dial (800) 715-9871 (Domestic) or (646) 307 1963 (International). The conference ID is 8444582. To access the live webcast, please go t

17 New ALLY® Adaptive Cataract Treatment Systems placed in 2Q 2024; highest number of placements since launch Received Medical Device Regulation (MDR) certification (CE Mark) and Taiwan FDA approval granted for commercial distribution of ALLY; First EU and Southeast Asia systems shipped Continued robust worldwide procedure growth; 2Q 2024 procedure volumes increased 19% over 2Q 2023 Installed system base grew 16% over 2Q 2023 LENSAR®, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2024 and provided an update on key

LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced that the Company's second quarter 2024 financial results will be released before market open on Thursday, August 8, 2024. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, August 8, 2024 to discuss the financial results and recent corporate highlights. To participate by telephone, please dial (800) 274 8461 (Domestic) or (203) 518 9848 (International). The conference ID is LENSAR. To access the live webcast, please go to the Investors section of LENSAR's website at www.lensar.com

Total Revenue increased 28% and Procedure volume increased 25% over the first quarter of 2023 Increased ALLY® Adaptive Cataract Treatment System installed base to 65 systems LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2024 and provided an update on key operational initiatives. "Recognition of ALLY's advantages, its ability to achieve higher efficiencies for surgeons and staff as well as better surgical outcomes for patients, allowed us to deliver continued 20%+ revenue growth in the first quart

LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company's first quarter 2024 financial results will be released before market open on Thursday, May 9, 2024. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, May 9, 2024 to discuss the financial results and recent corporate highlights. To participate by telephone, please dial (800) 267 6316 (Domestic) or (203) 518 9783 (International). The conference ID is LENSAR. To access the live webcast, please go to the Investors section of LENSAR's website at www.lensa

44 ALLY® Adaptive Cataract Treatment Systems were placed in 2023, significantly exceeding the target of 30, increasing the ALLY installed base to 54 and a backlog of 9 additional systems as of December 31, 2023 Total revenue increased 18% in the fourth quarter and 19% over full year 2022 LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter and full year ended December 31, 2023 and provided an update on key operational initiatives. "Our strong performance throughout 2023 continued in the fourth quarter, resulting in tot

LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company's fourth quarter and full year 2023 financial results will be released before market open on Monday, March 4, 2024. LENSAR's management will host a conference call and webcast at 8:30 am ET on Monday, March 4, 2024 to discuss the financial results and recent corporate highlights. To participate by telephone, please dial (888) 259 6580 (Domestic) or (206) 962 3782 (International). The conference ID number is 48034263. To access the live webcast, please go to the Investors section of LENSA

Increased ALLY® Adaptive Cataract Treatment System installed base to 39 systems with a backlog of 8 additional systems for installation as of September 30, 2023 Total revenue increased 26% and U.S. procedure volume increased 16% over the third quarter 2022 LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter ended September 30, 2023 and provided an update on key operational initiatives. "We have seen continued strength in our business in the third quarter, with total revenue up 26% and U.S. procedure volume increasing

LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company's third quarter 2023 financial results will be released before market open on Thursday, November 9, 2023. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, November 9, 2023 to discuss the financial results and recent corporate highlights. To participate by telephone, please dial (888) 660 5501 (Domestic) or (646) 960 0416 (International). The conference ID number is 7303394. To access the live webcast, please go to the Investors section of LENSAR's we

         24 ALLY Robotic Laser Cataract Systems™ placed in 3Q 2024 including 11 sales in EU and Southeast Asia; Robust backlog with 24 systems pending installation as of September 30, 2024 38% Revenue growth over third quarter 2023 and 22% Recurring revenue growth in twelve-month trailing average Worldwide procedure volumes increased 29% over third quarter of 2023 Installed system base grew 20% over third quarter of 2023 ORLANDO, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- LENSAR®, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter

ORLANDO, Fla., Nov. 01, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 650 shares of the Company's common stock. The options were granted as of November 1, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $5.38 per share, which is equal to the closing price of the Company's common stock on the grant date. The options vest as

ORLANDO, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's third quarter 2024 financial results will be released before market open on Thursday, November 7, 2024. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, November 7, 2024 to discuss the financial results and recent corporate highlights. To participate by telephone, please dial (800) 715-9871 (Domestic) or (646) 307 1963 (International). The conference ID is 8444582. To access the live webcast, please go t

ORLANDO, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that more than one million procedures have been performed using its technology. "We are proud to celebrate this significant milestone with our surgeon partners. Our mission is to bring innovative robotic laser solutions to cataract surgeons to help them improve clinical efficiencies and outcomes, while revolutionizing the patient and surgical experience," said Nick Curtis, President and CEO of LENSAR. "The completion of our millionth procedure is a testament t

ORLANDO, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 875 shares of the Company's common stock. The options were granted as of October 1, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $4.40 per share, which is equal to the closing price of the Company's common stock on the grant date. The options vest as to

LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 2,425 shares of the Company's common stock. The options were granted as of September 3, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $4.63 per share, which is equal to the closing price of the Company's common stock on the grant date. The options vest as to 25% of the total amount of the award on the

LENSAR®, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced that management will participate in two upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment Conference On-demand presentation available Monday, September 9, 2024 at 7:00 a.m. Eastern Time. Lake Street Capital Markets 8th Annual Best Ideas Growth Conference Management will conduct one-on-one meetings with institutional investors on September 12, 2024 in New York. The on-demand H.C. Wainwright presentation will be available beginning at 7:00 a.m. Eastern Time on Monday, September 9, 2

17 New ALLY® Adaptive Cataract Treatment Systems placed in 2Q 2024; highest number of placements since launch Received Medical Device Regulation (MDR) certification (CE Mark) and Taiwan FDA approval granted for commercial distribution of ALLY; First EU and Southeast Asia systems shipped Continued robust worldwide procedure growth; 2Q 2024 procedure volumes increased 19% over 2Q 2023 Installed system base grew 16% over 2Q 2023 LENSAR®, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2024 and provided an update on key

First EU ALLY Commercial Installation Planned for August 2024 LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced that the ALLY Adaptive Cataract Treatment System ("ALLY" or "ALLY System") has received certification under the European Union's ("EU") Medical Device Regulation ("MDR"). "We are thrilled to receive EU MDR certification for ALLY, which marks a significant milestone for LENSAR. We believe ALLY's commercial availability in the EU creates a significant growth opportunity for us, through the ability to provide new capabilities and advanced next-generation l

LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 1,925 shares of the Company's common stock. The options were granted as of August 1, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $5.20 per share, which is equal to the closing price of the Company's common stock on the grant date. The options vest as to 25% of the total amount of the award on the on

10-Q - LENSAR, Inc. (0001320350) (Filer)

8-K - LENSAR, Inc. (0001320350) (Filer)

10-Q - LENSAR, Inc. (0001320350) (Filer)

8-K - LENSAR, Inc. (0001320350) (Filer)

8-K - LENSAR, Inc. (0001320350) (Filer)

10-Q - LENSAR, Inc. (0001320350) (Filer)

8-K - LENSAR, Inc. (0001320350) (Filer)

8-K - LENSAR, Inc. (0001320350) (Filer)

ARS - LENSAR, Inc. (0001320350) (Filer)

DEFA14A - LENSAR, Inc. (0001320350) (Filer)

SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

SC 13D - LENSAR, Inc. (0001320350) (Subject)

SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

BTIG initiated coverage of LENSAR with a rating of Buy and set a new price target of $15.00

SVB Leerink initiated coverage of LENSAR with a rating of Outperform and set a new price target of $20.00

SVB Leerink initiated coverage of LENSAR with a rating of Outperform and set a new price target of $20.00

LENSAR (NASDAQ:LNSR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.28) by 32.14 percent. This is a 52.5 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $10.588 million which beat the analyst consensus estimate of $10.550 million by 0.36 percent. This is a 28.31 percent increase over sales of $8.252 million the same period last year.

Lake Street initiates coverage on LENSAR (NASDAQ:LNSR) with a Buy rating and announces Price Target of $8.

LENSAR (NASDAQ:LNSR) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.22) by 59.09 percent. This is a 45.83 percent decrease over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $12.11 million which beat the analyst consensus estimate of $12.00 million by 0.88 percent. This is a 18.31 percent increase over sales of $10.23 million the same period last year.

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its fourth quarter. • Avadel Pharmaceuticals (NASDAQ:AVDL) is projected to report quarterly loss at $0.29 per share on revenue of $18.11 million. • LENSAR (NASDAQ:LNSR) is expected to report quarterly loss at $0.22 per share on revenue of $12.00 million. • Sea (NYSE:SE) is projected to report quarterly loss at $0.27 per share on revenue of $3.53 billion. • Global Ship Lease (NYSE:GSL) is estimated to report quarterly earnings at $2.35 per share on revenue of $172.02 million. • Modiv Industrial (NYSE:MDV) is likely to report earnings for its fourth quarter. • GEO Group (NYSE:GEO) is estimat

LENSAR (NASDAQ:LNSR) is set to give its latest quarterly earnings report on Monday, 2024-03-04. Here's what investors need to know before the announcement. Analysts estimate that LENSAR will report an earnings per share (EPS) of $-0.22. LENSAR bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Historical Earnings Performance Last quarter the company beat EPS by $0.11, which was followed by a 0.44% increase in the share price the ne

LENSAR (NASDAQ:LNSR) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.34) by 32.35 percent. This is a 41.03 percent increase over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $9.79 million which missed the analyst consensus estimate of $10.20 million by 3.97 percent. This is a 26.42 percent increase over sales of $7.75 million the same period last year.

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million. • AstraZeneca (NASDAQ:AZN) is projected to report quarterly earnings at $0.84 per share on revenue of $11.66 billion. • Sony Group (NYSE:SONY) is projected to report quarterly earnings at $1.16 per share on revenue of $19.39 billion. • ArcelorMittal (NYSE:MT) is estimated to report earnings for its third quarter. • Wix.com (NASDAQ:WIX) is estimated to report quarterly earnings at $0.67 per share on revenue of $389.83 million. • Vanguard Extended Duration Treasury ETF (NYSE:EDV) is projected to report quarterly earnings at $0.26 per shar

LENSAR (NASDAQ:LNSR) is set to give its latest quarterly earnings report on Thursday, 2023-11-09. Here's what investors need to know before the announcement. Analysts estimate that LENSAR will report an earnings per share (EPS) of $-0.34. LENSAR bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Historical Earnings Performance Last quarter the company beat EPS by $0.09, which was followed by a 0.81% drop in the share price the next

Gainers AgileThought, Inc. (NASDAQ:AGIL) rose 96.5% to $0.3046 in pre-market trading after falling 17% on Tuesday. Digital Brands Group, Inc. (NASDAQ:DBGI) shares gained 57.9% to $13.33 in pre-market trading. DBGI effected a 1-for-25 reverse stock split on Tuesday. NanoVibronix, Inc. (NASDAQ:NAOV) shares climbed 49% to $2.18 in pre-market trading after the company reported outcomes from a UroShield study conducted at the University of Southampton in the U.K. Tingo Group, Inc. (NASDAQ:TIO) shares rose 42.4% to $1.21 in pre-market trading. Tingo Group announced completion of investigation into allegations made against the company in short-seller report and issued its response. Top Kin

Gainers NanoVibronix (NASDAQ:NAOV) stock increased by 71.0% to $2.48 during Wednesday's pre-market session. The company's market cap stands at $4.1 million. Aravive (NASDAQ:ARAV) stock moved upwards by 21.13% to $0.14. The market value of their outstanding shares is at $10.6 million. Dermata Therapeutics (NASDAQ:DRMA) stock increased by 18.81% to $1.2. The company's market cap stands at $3.8 million. AEON Biopharma (AMEX:AEON) stock rose 14.17% to $4.59. The company's market cap stands at $170.5 million. Akso Health Group (NASDAQ:AHG) shares increased by 12.01% to $0.82. The company's market cap stands at $18.6 million. Harvard Bioscience (NASDAQ:HBIO) stock moved upwards by 11.96% to